"Not for Human Consumption": A Review of Emerging Designer Drugs

被引:59
作者
Musselman, Megan E. [1 ]
Hampton, Jeremy P. [2 ,3 ]
机构
[1] North Kansas City Hosp, Kansas City, MO USA
[2] Univ Missouri, Sch Pharm, Kansas City, MO 64108 USA
[3] Univ Missouri, Truman Med Ctr, Kansas City, MO 64108 USA
来源
PHARMACOTHERAPY | 2014年 / 34卷 / 07期
关键词
designer drugs; cathinones; cannabinoids; psychostimulants; hallucinogens; Bromodragonfly; phenylethylamines; synthetic drugs; 2C agents; piperazine derivatives; CANNABINOID-RECEPTOR AGONISTS; CATHINONES BATH SALTS; SYNTHETIC CANNABINOIDS; MASS-SPECTROMETRY; RECREATIONAL USE; CARDIAC-ARREST; ABUSE; SPICE; 1-BENZYLPIPERAZINE; TOXICOLOGY;
D O I
10.1002/phar.1424
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Synthetic, or "designer" drugs, are created by manipulating the chemical structures of other psychoactive drugs so that the resulting product is structurally similar but not identical to illegal psychoactive drugs. Originally developed in the 1960s as a way to evade existing drug laws, the use of designer drugs has increased dramatically over the past few years. These drugs are deceptively packaged as "research chemicals," "incense," "bath salts," or "plant food," among other names, with labels that may contain warnings such as " not for human consumption" or "not for sale to minors." The clinical effects of most new designer drugs can be described as either hallucinogenic, stimulant, or opioid-like. They may also have a combination of these effects due to designer side-chain substitutions. The easy accessibility and rapid emergence of new designer drugs have created challenges for health care providers when treating patients presenting with acute toxicity from these substances, many of which can produce significant and/or life-threatening adverse effects. Moreover, the health care provider has no way to verify the contents and/or potency of the agent ingested because it can vary between packages and distributors. Therefore, a thorough knowledge of the available designer drugs, common signs and symptoms of toxicity associated with these agents, and potential effective treatment modalities are essential to appropriately manage these patients.
引用
收藏
页码:745 / 757
页数:13
相关论文
共 80 条
[1]  
American Association of Poison Control Centers, 2013, BATH SALTS
[2]  
American Association of Poison Control Centers, 2013, SYNTH MAR
[3]   A fatal poisoning involving Bromo-Dragonfly [J].
Andreasen, Mette Findal ;
Telving, Rasmus ;
Birkler, Rune Isak Dupont ;
Schumacher, Bente ;
Johannsen, Mogens .
FORENSIC SCIENCE INTERNATIONAL, 2009, 183 (1-3) :91-96
[4]  
[Anonymous], 2014, FED REGISTER, V79, P1776
[5]  
[Anonymous], 2012, MORBIDITY MORTALITY
[6]  
Antia U, 2009, NEW ZEAL MED J, V122, P55
[7]   Piperazine compounds as drugs of abuse [J].
Arbo, M. D. ;
Bastos, M. L. ;
Carmo, H. F. .
DRUG AND ALCOHOL DEPENDENCE, 2012, 122 (03) :174-185
[8]   The new danger of synthetic drugs [J].
Arnold, Carrie .
LANCET, 2013, 382 (9886) :15-16
[9]   Psychiatric Sequelae of Spice, K2, and Synthetic Cannabinoid Receptor Agonists [J].
Benford, Dawn M. ;
Caplan, Jason P. .
PSYCHOSOMATICS, 2011, 52 (03) :295-295
[10]   INFLUENCE OF LABETALOL ON COCAINE-INDUCED CORONARY VASOCONSTRICTION IN HUMANS [J].
BOEHRER, JD ;
MOLITERNO, DJ ;
WILLARD, JE ;
HILLIS, LD ;
LANGE, RA .
AMERICAN JOURNAL OF MEDICINE, 1993, 94 (06) :608-610